Replimune sinks 57% on second FDA rejection of melanoma drug; stock downgraded

Investing.com Gold reports: Replimune sinks 57% on second FDA rejection of melanoma drug; stock downgraded. Full body text was unavailable at ingest time, so this brief is based on headline context.